Organization
Zentalis Pharmaceuticals
2 abstracts
Abstract
Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.Org: Zentalis Pharmaceuticals,
Abstract
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,